Studies have shown that hepatitis C virus (HCV) RNA levels remain stable over time in HIV/HCVcoinfected individuals taking combination antiretroviral therapy (cART), while spontaneous clearance of HCV RNA during the persistent infection phase has been documented only rarely among those with the CC interleukin (IL)-28B genotype. This study describes HCV RNA profiles and factors associated with changes over time in HCV RNA levels in the ESPRIT study.
Introduction
When used together with combination antiretroviral therapy (cART), subcutaneous recombinant interleukin (IL)-2 is known to raise the CD4 cell count more than cART alone [1] . The Evaluation of Subcutaneous Proleukin â in a Randomized International Trial (ESPRIT) trial randomized HIV-positive individuals with CD4 cell count > 300 cells/lL to receive IL-2 plus antiretroviral therapy or antiretroviral therapy alone, with the aim of comparing the rates of opportunistic disease or death from any cause [1] . Although the study concluded that substantial increases in CD4 cell count associated with the administration of IL-2 in addition to cART did not yield any benefit with regard to clinical endpoints [1] , other studies have shown that IL-2 may be associated with suppression of hepatitis C virus (HCV) RNA in HIV/HCV-coinfected individuals. Small pilot studies have shown that IL-2 treatment for HCV infection may lead to a reduction in liver transaminases, improvement in liver function tests and in some cases sustained suppression of HCV RNA [2, 3] .
Where new direct-acting antivirals are not available because of cost or supply issues, interferon-based treatment for HCV infection remains the standard of care among HIV/ HCV-coinfected individuals [4] . Plasma HCV RNA levels and IL-28B gene variant have been shown to be two of the most important predictors of sustained virological response (SVR) to treatment with pegylated-interferon plus ribavirin [5, 6] . Consequently, it is important to understand which factors are associated with high levels of HCV RNA and which affect changes over time in HCV RNA levels.
One study of 264 HIV/HCV-coinfected individuals actively injecting drugs found that HCV RNA levels increased slowly but significantly over time by approximately 6% each year [7] . Another larger study of 1541 HIV/HCV-coinfected individuals, which focused on the effect of HIV therapy on the course of HCV RNA, found that, among those taking cART, HCV RNA levels remained stable over time, but that for those not taking cART they increased by 27.6% each year [8] . Further, both studies identified HCV genotype 1 and high levels of HIV RNA as significant predictors of high levels of HCV RNA [7, 8] .
The CC variant of the IL-28B gene, has been strongly associated with a superior response to treatment with pegylated-interferon in HCV-monoinfected and HIV/HCVcoinfected individuals and also an increased likelihood of spontaneous clearance of HCV RNA following initial infection [9] . In addition, small observational studies of HIV/HCV-coinfected individuals in the persistent infection phase have identified spontaneous clearance of HCV RNA in a handful of individuals, all with the IL-28B CC gene variant [10] . This study aimed to describe the natural history of HCV RNA among HIV/HCV-coinfected individuals in the persistent infection phase in the ESPRIT study, and to consider the effect of IL-2, among other factors, on HCV RNA levels over time.
Methods
All chronically HIV/HCV-coinfected individuals enrolled in the ESPRIT study who were positive for HCV antibody and HCV RNA were included in the study. Baseline was defined as entry to the study, while follow-up was censored at the initiation of interferon-based treatment for HCV or the date of spontaneous clearance of HCV RNA. HCV RNA measurements were taken at study entry and annually during follow-up. A random effects mixed model was used to analyse changes over time in HCV RNA measured on the log 10 scale. The covariates adjusted for were ESPRIT randomization arm (IL-2 or control arm), randomization date, age, gender, race, study region, injecting drug use (IDU), HCV genotype, time from baseline, CD4 cell count nadir, and the time-updating variables HIV RNA, CD4 cell count, hyaluronic acid and cART status (taking cART, yes or no, defined as at least three antiretrovirals from any class). The intercept and time from baseline terms were included as random variables so that separate slopes could be estimated for each individual in the analysis. An unstructured covariance structure was used throughout.
Individuals who spontaneously cleared HCV RNA during the chronic phase of infection were cross-checked with clinical sites to ensure that interferon-based treatment had not been administered and were IL-28B genotyped. All HCV RNA measurements and IL-28B genotyping determinations were performed in the same reference laboratory. HCV RNA measurements were performed using the Versant HCV RNA 3.0 assay (Bayer Diagnostics, Berkeley, CA, United States), which has a lower limit of detection of 615 IU/mL. Baseline and all follow-up samples were tested for each individual. The IL-28B polymorphism test is a polymerase chain reaction analysis of a single nucleotide polymorphism (rs12979860) requiring whole blood.
Results
Three hundred and twelve chronically HIV/HCV-coinfected individuals from ESPRIT were included in the study (151 from the IL-2 arm and 161 from the control arm). The study follow-up period was from Table 1) .
The majority of individuals included were male (78.2% in the IL-2 arm vs. 73.9% in the control arm), of white race (88.1 vs. 90.1%, respectively) and aged < 40 years (63.6% vs. 54.7%, respectively). A large proportion were infected with HIV via IDU (76.2 vs. 66.5%, respectively), but few individuals were also coinfected with hepatitis B virus (HBV; 2.9 vs. 0.7%, respectively). The most common HCV genotypes were G1 (58.9 vs. 57.1%, respectively) and G3 (19.9 vs. 19.9%, respectively). The majority of individuals were taking cART (96.0 vs. 95.0%, respectively) and consequently few had detectable HIV RNA (5.3 vs. 8.7%, respectively) and median CD4 cell counts were high (434 vs. 435 cells/lL, respectively).
Factors associated with HCV RNA levels
Overall, mean HCV RNA levels decreased by 12.8% per year over the study period [95% confidence interval (CI) 7.6À17.8%; P < 0.0001], while nine individuals spontaneously cleared HCV RNA during the chronic phase of infection. Omitting the nine individuals who cleared HCV RNA during follow-up, mean HCV RNA levels decreased by 11.7% per year (95% CI: 6.4-16.7%; P < 0.0001). Baseline levels of HCV RNA were significantly associated with HCV genotype and HIV RNA. HCV genotype 3 was associated with 64.7% lower mean HCV RNA than HCV genotype 1 (95% CI: 43.5-77.9%; P < 0.0001), while undetectable HIV RNA was associated with 20.4% lower mean HCV RNA compared with HIV viral load above the limit of detection (95% CI: 3.7-34.2%; P = 0.019). Older age was also associated with higher HCV RNA, with borderline statistical significance (mean 13.8% higher per 5 years older; 95% CI: À1.3-31.4%; P = 0.075).
An interaction term between randomization arm and time from baseline was added to the model to see whether the rate of HCV RNA decline over time was affected by the addition of IL-2. Baseline levels of HCV RNA appeared to be somewhat higher among those in the IL-2 randomization arm and the rate of decline in HCV RNA over time somewhat faster (Fig. 1) . However, neither effect approached statistical significance and there was no evidence to suggest that randomization arm was associated with baseline HCV RNA levels or the rate of decline in HCV RNA over time (P = 0.16 and P = 0.56, respectively). Interaction terms including the other covariates were also nonsignificant (all P > 0.3; data not shown), indicating that none of the model covariates were significantly associated with the rate of decline in HCV RNA.
Spontaneous HCV RNA clearance and IL-28B genotype
There were nine cases of spontaneous HCV RNA clearance during the persistent infection phase of HCV infection over the course of the study. The IL-28B genotypes of these individuals were: CC, five of nine patients (55.6%); CT, four patients (44.4%); none of them had the TT genotype. The median age of these nine patients was 38 years (IQR: 36À42 years), five of nine (55.6%) were male and eight of nine (88.9%) were of white race; the other was Asian. None of these individuals were HBV surface antigen (HBsAg) positive, although for one of them HBsAg status was unknown. The HCV genotype distribution in these nine individuals was: G1, three patients (33.3%); G2, one patient (11.1%); and G3, five patients (55.6%), while the median baseline HCV RNA was 6.01 log 10 IU/mL (IQR: 4.60-6.13 log 10 IU/mL). The median duration of follow-up prior to becoming negative for HCV RNA was 24 months (IQR: 12-72 months; range 12À84 months). The median nadir CD4 cell count in these patients was 199 cells/mL (IQR: 155À352 cells/lL), the median CD4 cell count at spontaneous clearance was 435 cells/lL (IQR: 400À702 cells/lL), and HIV RNA was undetectable for five of the nine patients (55.6%).
Discussion
This study of chronically HIV/HCV-coinfected individuals documented a significant decline in HCV RNA levels over time. This finding is in agreement with a recent study of a small number of HIV/HCV-coinfected individuals enrolled in a cART initiation trial [11] . The authors found that a transient increase in HCV RNA may result from initiation of cART; however, in the long term, up-regulation of CD4, CD8 and alpha-beta T-cell activity was demonstrated to lead to a decline in HCV RNA [11] . Other studies of the natural history of HCV RNA have tended to suggest that HCV RNA levels remain fairly stable over time [7, 8] . One of the strengths of this study is that all HCV RNA measurements were determined in the same reference laboratory, which is not always the case in many observational settings, and could be a contributor to the contradictory findings of this study and others looking at the natural history of HCV RNA. However, this study differs from previous studies in that it included individuals enrolled in a clinical trial who had very wellcontrolled HIV infection. At baseline, > 95% of the 312 individuals included in the study were taking cART and only 7.1% had detectable HIV RNA. In addition, detectable HIV RNA was associated with significantly higher levels of HCV RNA, which confirms the findings of previous studies and suggests that control of HIV RNA following cART can lead to an improved cellular response to HCV [8, 12] . HCV genotype 1 was associated with higher levels of HCV RNA compared with other genotypes, in particular HCV genotype 3. This finding is in agreement with other studies on the topic and, while high levels of HCV RNA are associated with a poor response to treatment with pegylated-interferon, may help to explain the comparatively low rate of SVR seen for these treatments in HCV genotype 1 [6] [7] [8] 13] . The design of this study allowed for direct comparison of HCV RNA profiles among HIV/HCVcoinfected individuals receiving cART alone and IL-2 in addition to cART. While treatment with IL-2 has previously been associated with an improvement in liver function and suppression of HCV RNA in some cases [2, 3] , this study found no evidence to suggest that the addition of IL-2 had any long-term effect on the course of HCV RNA. However, IL-2 was administered twice daily for 5 days on an 8-week cycle, while HCV RNA measurements were taken annually. Therefore, we might not have been able to detect the effect of IL-2 on HCV RNA levels if the effect was only transient.
The IL-28B CC gene variant is known to be associated with a favourable response to interferon-based treatments for HCV infection and an increased likelihood of spontaneous clearance following initial HCV infection [9, 14] . Further, in studies of HIV/HCV coinfection where a small number of individuals with the CC gene variant have spontaneously cleared HCV RNA during the persistent infection phase, it has been suggested that immune reconstitution as a result of successful cART may lead to the resumption of the mechanisms responsible for Test for interaction (different slopes) P = 0.56 Fig. 1 The effect of ESPRIT randomization arm on the course of hepatitis C virus (HCV) RNA levels. IL, interleukin.
clearance of HCV RNA [10, 14] . This study documented HCV RNA spontaneous clearance during the persistent infection phase in five individuals with the CC gene variant and four individuals with the CT gene variant. This is the first study to document spontaneous clearance of HCV RNA during the persistent infection phase in individuals with the CT IL-28B gene variant, which suggests that the spontaneous HCV RNA clearance phenomenon during persistent infection is not restricted to the CC gene variant.
